Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatmentsCNBC • 01/31/24
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024Accesswire • 01/30/24
Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 01/29/24
These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall StreetThe Motley Fool • 01/18/24
Biogen Inc. (BIIB) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 01/10/24
Biogen Inc. (BIIB) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)Seeking Alpha • 01/08/24
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024Investors Business Daily • 01/05/24
Biogen Inc. (BIIB) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 01/04/24
Biogen Inc. (BIIB) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 12/29/23
Biogen ‘welcomes' EC decision to revoke CMAs for generic versions of TecfideraMarket Watch • 12/19/23
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European CommissionGlobeNewsWire • 12/19/23
CHMP Issues Positive Opinion for Biogen's SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative DiseaseGlobeNewsWire • 12/15/23